# HiveProspect full machine-readable guide

Hive Prospect is a biotech decision-intelligence system focused on Cost-to-Truth: the cheapest credible path to the next useful development decision.

## Free tools
- Clinical Trial Cost Calculator: https://prospect.hive.baby/clinical-trial-cost-calculator — transparent arithmetic from user-entered cost assumptions; blanks remain UNKNOWN.
- Protocol Complexity Calculator: https://prospect.hive.baby/protocol-preflight — heuristic warning lights for cost, enrollment and amendment risk; not a validated clinical score.
- Clinical Trial Enrollment Calculator: https://prospect.hive.baby/trial-enrollment-calculator — screens required, recruitment months, startup delay and completers from explicit assumptions.
- Clinical Trial Country Comparison: https://prospect.hive.baby/clinical-trial-country-comparison — apples-to-apples geography scenarios from explicit site, startup, enrollment, cost and incentive assumptions.

## Methodology and evidence
- https://prospect.hive.baby/methodology — formulas, assumptions, limitations, Tufts CSDD, CTTI and FDA references.
- Evidence policy: FACT is sourced or entered; INFERENCE is reviewable assessment; UNKNOWN remains unresolved.

## Paid products
- Protocol Cost & Complexity Audit: $99 pilot via https://prospect.hive.baby/protocol-preflight
- Trial Geography Review: $499 at https://prospect.hive.baby/products/geography-review
- Recruitment Feasibility Review: $499 at https://prospect.hive.baby/products/recruitment-review
- Site Feasibility Review: $499 at https://prospect.hive.baby/products/site-review
- CRO & Vendor Cost Review: $499 at https://prospect.hive.baby/products/cro-cost-review
- Protocol Simplification Review: $499 at https://prospect.hive.baby/products/protocol-redesign

## Worked example
- https://prospect.hive.baby/protocol-audit/example

## External discovery references
- https://machineoverhuman.com/
- https://newphysician.org/healthcare/
- https://biotech.rightengines.com/
- https://hiveprospect.xeosystem.com/
- https://hiveprospect.universaldocument.org/

## Learning center
- https://prospect.hive.baby/learn/how-much-does-a-phase-1-clinical-trial-cost — How Much Does a Phase 1 Clinical Trial Cost?: There is no single honest Phase 1 price. The useful answer is a transparent budget built from protocol, site, patient, geography and vendor assumptions.
- https://prospect.hive.baby/learn/clinical-trial-cost-breakdown — Clinical Trial Cost Breakdown: What Actually Drives the Budget?: A trial budget is a stack of patient, site, vendor, geography and time costs. The fastest way to understand it is to make every bucket explicit.
- https://prospect.hive.baby/learn/phase-1-us-vs-australia — Phase 1 in the U.S. vs Australia: How Should You Compare Cost?: Do not compare countries as if each has one price. Compare actual capable sites, startup path, recruitment, incentives, logistics and evidence value.
- https://prospect.hive.baby/learn/trial-country-selection — How to Choose a Country for a Clinical Trial: Country selection should optimize credible time-to-answer, not prestige, habit or a generic cost table.
- https://prospect.hive.baby/learn/how-many-sites-do-i-need — How Many Sites Does a Clinical Trial Need?: More sites can increase recruitment capacity, but every site adds startup, monitoring and management burden. The answer depends on credible enrollment per site.
- https://prospect.hive.baby/learn/trial-enrollment-forecast — How to Build a Clinical Trial Enrollment Forecast That Is Not Fiction: Enrollment forecasts fail when they multiply optimistic site estimates by the number of sites. Build the forecast from protocol-specific evidence.
- https://prospect.hive.baby/learn/screen-failure-cost — Clinical Trial Screen Failure: Why It Can Quietly Explode Cost: A high screen-failure rate means you must find and evaluate far more people than the enrollment target suggests.
- https://prospect.hive.baby/learn/patient-burden-recruitment — Patient Burden Is a Trial-Cost Variable: Travel, caregiver needs, painful procedures and long visits affect recruitment, retention and the number of sites you may need.
- https://prospect.hive.baby/learn/protocol-complexity-cost — How Protocol Complexity Drives Clinical Trial Cost: Complexity is expensive when it creates visits, procedures, vendors, site burden and data that do not change a decision.
- https://prospect.hive.baby/learn/protocol-amendment-risk — How to Spot Clinical Trial Protocol Amendment Risk Before Startup: Amendments become expensive after sites open. The best time to pressure-test complexity is before the study network is committed.
- https://prospect.hive.baby/learn/site-feasibility-questions — Clinical Trial Site Feasibility: Questions That Actually Matter: The best feasibility questions test whether a site can execute this exact protocol and enroll this exact population.
- https://prospect.hive.baby/learn/site-startup-time — Clinical Trial Site Startup Time: What Slows It Down?: Startup delay is usually a chain of contracts, budgets, regulatory/ethics work, pharmacy, training and vendor dependencies rather than one single clock.
- https://prospect.hive.baby/learn/cro-cost-breakdown — CRO Cost Breakdown: What Are You Actually Paying For?: A CRO proposal is a bundle of work. Unbundle it enough to understand which tasks buy evidence and which are coordination overhead.
- https://prospect.hive.baby/learn/cro-proposal-comparison — How to Compare CRO Proposals Apples-to-Apples: Do not compare bottom-line totals until you normalize assumptions, units, pass-throughs, exclusions and escalation rules.
- https://prospect.hive.baby/learn/cost-to-truth — Cost-to-Truth: A Better Way to Think About Clinical Development Spend: Cost-to-Truth asks how much time and money are required to obtain the next credible answer that changes a management decision.
- https://prospect.hive.baby/learn/indication-prioritization-biotech — How to Prioritize Indications in Early Biotech Development: The biggest market is not always the best first indication. Early development often benefits from the population that gives the cleanest human proof.
- https://prospect.hive.baby/learn/asset-licensing-diligence — Biotech Licensing Diligence: What to Check Before Spending Months on a Deal: Resolve whether the asset is actionable before building an elaborate valuation.
- https://prospect.hive.baby/learn/stranded-asset-diligence — How to Evaluate a Stranded or Discontinued Biotech Asset: A discontinued program can reflect biology, financing, strategy, execution or corporate events. Classify the reason before classifying the asset.
- https://prospect.hive.baby/learn/first-human-proof — What Should a First-in-Human Trial Prove Besides Safety?: A first-in-human study can be designed to create strategic evidence, not merely complete a conventional Phase 1 checklist.
- https://prospect.hive.baby/learn/protocol-procedure-value — Does Every Procedure in Your Clinical Trial Protocol Earn Its Keep?: Every procedure should protect safety, support the primary evidence objective, or change a defined decision.
- https://prospect.hive.baby/learn/clinical-trial-cost-overruns — Why Clinical Trial Budgets Overrun: Overruns usually come from assumptions that were wrong, scope that was incomplete, or complexity that became expensive after startup.